Phase 3 Recruiting Industry
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in Connecticut: - Hartford Hospital — Hartford, Connecticut
- Yale Cancer Center — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy…
Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT07038343
Sites in Connecticut: - Avenzo Therapeutics Recruiting Site — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Sponsor: GV20 Therapeutics
NCT ID: NCT05669430
Sites in Connecticut: - Yale University — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with s…
Sponsor: Alentis Therapeutics AG
NCT ID: NCT06747585
Sites in Connecticut: - Yale Comprehensive Cancer Center — New Haven, Connecticut
Phase 1, Phase 2 Recruiting Industry
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatment, by IV infusion, and in combination …
Sponsor: Simcha IL-18, Inc.
NCT ID: NCT04787042
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 2 Recruiting Industry
This will be a multi-center, randomized, open-label, parallel-group study in adult patients with head and neck cancer.
Sponsor: VSPharmTech Co.,Ltd.
NCT ID: NCT06959082
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 2 Recruiting Academic/Other
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent cervical cancer.
Sponsor: Yale University
NCT ID: NCT05838521
Sites in Connecticut: - Smilow Cancer Hospital at Yale New Haven — New Haven, Connecticut
Phase 2 Recruiting Academic/Other
This is a phase 2, pilot, randomized, open-label 3-arm study to assess the safety, tolerability, and efficacy of CUE-101 monotherapy, and CUE-101 in combination with pembrolizumab as neoadjuvant therapy in HLA-A\*0201-positive treatment na…
Sponsor: Yale University
NCT ID: NCT07172256
Sites in Connecticut: - Yale University — New Haven, Connecticut
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Connecticut: - Yale Cancer Center — New Haven, Connecticut
Phase 1 Recruiting Industry
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Sponsor: IDEAYA Biosciences
NCT ID: NCT05787587
Sites in Connecticut: - Yale University — New Haven, Connecticut
Phase 1 Recruiting Industry
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
Sponsor: Normunity AccelCo, Inc.
NCT ID: NCT07182149
Sites in Connecticut: - Normunity Investigational Site — New Haven, Connecticut
Phase 1 Recruiting Industry
The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expr…
Sponsor: EMD Serono Research & Development Institute, Inc.
NCT ID: NCT07360314
Sites in Connecticut: - Yale University - Yale University School of Medicine — New Haven, Connecticut
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Connecticut: - Veterans Affairs Connecticut Healthcare System-West Haven Campus — West Haven, Connecticut
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Connecticut: - Massive Bio SYNERGY-AI site — Hartford, Connecticut
- Massive Bio SYNERGY-AI site — Norwalk, Connecticut
Recruiting Industry
The purpose of this prospective cohort study is to assess clinical and quality of life measures as well as to define the severity of adverse effects for the use of the RefleXion system to deliver intensity-modulated radiotherapy (IMRT), st…
Sponsor: RefleXion Medical
NCT ID: NCT05406167
Sites in Connecticut: - Yale University - Cancer Center — New Haven, Connecticut